At the present time, the standard of care for patients who have received nephrectomy for localized renal cell carcinoma (RCC) is radiographic surveillance.
With a number of novel targeted agents showing activity in the setting of metastatic RCC, there has been great interest in exploring the potential of the same agents in the adjuvant setting. Herein, we discuss the evolution of adjuvant trials in RCC, spanning from the immunotherapy era to the targeted therapy era. Pitfalls of current studies are addressed to provide a context for interpreting forthcoming results. Finally, we outline avenues to incorporate promising investigational agents, such as PD-1 (programmed death-1) inhibitors and MNNG transforming gene inhibitors, in future adjuvant trials.
Written by:
Pal SK, Haas NB. Are you the author?
Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA; Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Reference: Oncologist. 2014 Aug;19(8):851-859.
doi: 10.1634/theoncologist.2014-0105
PubMed Abstract
PMID: 24969163
UroToday.com Renal Cancer Section
